Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet.

Autor:	Lennerz BS; Division of Endocrinology, and.; New Balance Foundation Obesity Prevention Center, Boston Children's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts., Barton A; Richmond Diabetes and Endocrinology, Bon Secours Medical Group, Richmond, Virginia., Bernstein RK; New York Diabetes Center, Mamaroneck, New York., Dikeman RD; Lockheed Martin, Honolulu, Hawaii., Diulus C; Crystal Clinic Orthopaedic Center, Akron, Ohio., Hallberg S; Virta Health and Indiana University Health, School of Medicine, Indiana University, Indianapolis, Indiana; and., Rhodes ET; Division of Endocrinology, and., Ebbeling CB; Division of Endocrinology, and.; New Balance Foundation Obesity Prevention Center, Boston Children's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts., Westman EC; Duke University Medical Center, Durham, North Carolina., Yancy WS Jr; Duke University Medical Center, Durham, North Carolina., Ludwig DS; Division of Endocrinology, and david.ludwig@childrens.harvard.edu.; New Balance Foundation Obesity Prevention Center, Boston Children's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Pediatrics [Pediatrics] 2018 Jun; Vol. 141 (6). Date of Electronic Publication: 2018 May 07.
DOI:	10.1542/peds.2017-3349
Abstrakt:	Objectives: To evaluate glycemic control among children and adults with type 1 diabetes mellitus (T1DM) who consume a very low-carbohydrate diet (VLCD). Methods: We conducted an online survey of an international social media group for people with T1DM who follow a VLCD. Respondents included adults and parents of children with T1DM. We assessed current hemoglobin A1c (HbA1c) (primary measure), change in HbA1c after the self-reported beginning of the VLCD, total daily insulin dose, and adverse events. We obtained confirmatory data from diabetes care providers and medical records. Results: Of 316 respondents, 131 (42%) were parents of children with T1DM, and 57% were of female sex. Suggestive evidence of T1DM (based on a 3-tier scoring system in which researchers took into consideration age and weight at diagnosis, pancreatic autoimmunity, insulin requirement, and clinical presentation) was obtained for 273 (86%) respondents. The mean age at diagnosis was 16 ± 14 years, the duration of diabetes was 11 ± 13 years, and the time following a VLCD was 2.2 ± 3.9 years. Participants had a mean daily carbohydrate intake of 36 ± 15 g. Reported mean HbA1c was 5.67% ± 0.66%. Only 7 (2%) respondents reported diabetes-related hospitalizations in the past year, including 4 (1%) for ketoacidosis and 2 (1%) for hypoglycemia. Conclusions: Exceptional glycemic control of T1DM with low rates of adverse events was reported by a community of children and adults who consume a VLCD. The generalizability of these findings requires further studies, including high-quality randomized controlled trials. Competing Interests: POTENTIAL CONFLICT OF INTEREST: Dr Bernstein reported receiving royalties for books on the management of diabetes (which were used by members of the online social media group surveyed in this study). Dr Hallberg reported stock options and research support from Virta Health, a company that provides health care services for type 2 diabetes, and consulting fees from Atkins. Dr Rhodes is the site principal investigator in clinical trials for pediatric type 2 diabetes that are sponsored by Merck and AstraZeneca. Dr. Westman has ownership interest in companies using low-carbohydrate principles, and he receives royalties for books related to low-carbohydrate diets. Dr Ludwig reported receiving royalties from books on nutrition and obesity; the other authors have indicated they have no potential conflicts of interest to disclose. (Copyright © 2018 by the American Academy of Pediatrics.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu